NCT04996160 2026-04-17
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed
Clinical Trials
7 trialsNCT00092222 2026-04-14
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01695941 2026-04-13
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07513129 2026-04-13
A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04433156 2026-04-09
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Completed
NCT00720785 2026-04-01
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00428142 2026-03-27
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed